抗结核药物致药物性皮疹并发肝损伤患者抗痨方案重整一例
A Case of Anti-Tuberculosis Regimen Reconstruction for a Patient with Drug-Induced Rash and Liver Injury Caused by Anti-Tuberculosis Drugs
DOI: 10.12677/hjbm.2025.151012, PDF,   
作者: 全明霞, 王慧如, 王昌文, 李花蓉:大理大学药学院,云南 大理;陈永刚*:昆明市第三人民医院药学部,云南 昆明
关键词: 抗结核药物药物性皮疹肝损伤抗痨方案重整特异性生物标志物Anti-TB Drugs Drug-Induced Rash Liver Injury Regimen Reconstruction Specific Biomarkers
摘要: 文章详细报道了一例在使用抗结核药物后出现药疹并发肝损伤的病例。患者在抗结核治疗期间,出现类似皮肤过敏反应的症状,经详细检查和评估,考虑为抗结核药物导致的药物性皮疹同时并发肝损伤。经对症处理及保肝治疗后,患者药疹症状缓解,待肝功能恢复正常,通过药物激发试验,给患者逐一试用抗结核药物并重新引入抗痨方案。本病例提示临床医生在使用抗结核药物时,需密切关注患者的皮肤状况及肝肾功能指标,以早期发现并处理药物不良反应。且通过对该病例的诊断和治疗过程进行详细地分析和总结,旨在增强临床工作者对抗结核药使用过程中可能出现的副作用的认识,并为临床实践提供参考和借鉴。
Abstract: A case of drug-induced rash and concomitant liver injury following anti-TB therapy was reported in detail. During treatment, the patient developed symptoms resembling a skin allergic reaction. Comprehensive examination and evaluation confirmed that the rash and liver injury were caused by anti-TB drugs. Symptomatic management and hepatoprotective treatment were provided, resulting in symptom resolution. Once liver function normalized, anti-TB drugs were reintroduced sequentially through drug challenge tests, and the anti-TB regimen was successfully restructured. This case underscored the need for clinicians to closely monitor skin and hepatic function during anti-TB therapy to detect and manage adverse drug reactions early. The detailed analysis of this case aimed to enhance clinical awareness of potential adverse effects associated with anti-TB drugs and provide practical guidance for clinical decision-making.
文章引用:全明霞, 王慧如, 王昌文, 李花蓉, 陈永刚. 抗结核药物致药物性皮疹并发肝损伤患者抗痨方案重整一例[J]. 生物医学, 2025, 15(1): 111-116. https://doi.org/10.12677/hjbm.2025.151012

参考文献

[1] 中华医学会, 中华医学会杂志社, 中华医学会皮肤性病学分会, 等. 药疹基层诊疗指南(2022年) [J]. 中华全科医师杂志, 2022, 21(9): 804-813.
[2] 龙明立, 刘芳群, 曾建国, 等. 6例典型抗结核药物引起的药物性皮炎病例分析[J]. 中南药学, 2014, 12(4): 377-378.
[3] 周书会, 王惠平. 抗结核药物所致药物性皮炎282例临床分析[J]. 中国皮肤性病学杂志, 2021, 35(2): 156-159.
[4] 陈鑫. 一线抗结核药致药疹的Meta分析[D]: [硕士学位论文]. 唐山: 华北理工大学, 2023.
[5] 李阳, 巴雪, 菅凌燕. 吡嗪酰胺药物不良反应临床使用的分析[J]. 中国临床药理学杂志, 2020, 36(4): 453-455.
[6] Shu, Y., Zhang, Q., He, X., Liu, Y., Wu, P. and Chen, L. (2022) Fluoroquinolone-Associated Suspected Tendonitis and Tendon Rupture: A Pharmacovigilance Analysis from 2016 to 2021 Based on the FAERS Database. Frontiers in Pharmacology, 13, Article 990241. [Google Scholar] [CrossRef] [PubMed]
[7] 张宏, 邝浩斌, 覃红娟, 等. 利奈唑胺所致47例耐多药肺结核患者不良反应分析[J]. 中国防痨杂志, 2018, 40(1): 73-79.
[8] 中华医学会结核病学分会, 抗结核药物超说明书用法专家共识编写组. 抗结核药物超说明书用法专家共识[J]. 中华结核和呼吸杂志, 2018, 41(6): 447-460.
[9] 环丝氨酸治疗结核病的临床用药指南[J]. 临床医学研究与实践, 2020, 5(19): 201.
[10] 孙晨, 王华. 药物激发试验在药物超敏反应诊断中的应用[J]. 国际皮肤性病学杂志, 2016, 42(4): 230-232.
[11] 中华医学会结核病学分会. 抗结核药物性肝损伤诊治指南(2019年版) [J]. 中华结核和 呼吸杂志, 2019, 42(5): 343-356.
[12] 翁汭, 高天琦, 李繁林, 等. 利福喷丁与利福平治疗肺结核安全性比较的Meta分析[J]. 中国循证医学杂志, 2017, 17(11): 1291-1297.
[13] 叶龙玲. 1例利福平致迟发性过敏反应[J]. 世界最新医学信息文摘, 2019, 19(25): 191.
[14] 王彬彬. 观察比较利福喷丁与利福平治疗肺结核的疗效和不良反应[J]. 现代医学与健康研究电子杂志, 2024, 8(7): 136-138.
[15] 中华医学会结核病学分会, 《中华结核和呼吸杂志》编辑委员会. 抗结核药所致药物性肝损伤诊断与处理专家建议[J]. 中华结核和呼吸杂志, 2013, 36(10): 732-736.
[16] 刘娟, 黄锐, 张晶, 等. 222例抗结核药致药物性肝损伤患者临床特征及预后分析[J]. 中国药业, 2022, 31(23): 57-61.
[17] 钟洪兰. 抗结核药物致肝损伤的预防与治疗药物选择[J]. 实用医学杂志, 2020, 36(24): 3307-3311.
[18] Wang, Y., Lai, R., Zong, P., Xu, Q., Shang, J., Zhang, X., et al. (2021) Bicyclol for the Treatment of Drug-Induced Liver Injury: A Propensity Score Matching Analysis Using a Nationwide Inpatient Database. Journal of International Medical Research, 49. [Google Scholar] [CrossRef] [PubMed]
[19] Wang, Y., Wang, Z., Gao, M., Zhong, H., Chen, C., Yao, Y., et al. (2019) Efficacy and Safety of Magnesium Isoglycyrrhizinate Injection in Patients with Acute Drug‐Induced Liver Injury: A Phase II Trial. Liver International, 39, 2102-2111. [Google Scholar] [CrossRef] [PubMed]
[20] Tang, J., Gu, J., Chu, N., Chen, Y., Wang, Y., Xue, D., et al. (2022) Efficacy and Safety of Bicyclol for Treating Patients with Idiosyncratic Acute Drug‐Induced Liver Injury: A Multicenter, Randomized, Phase II Trial. Liver International, 42, 1803-1813. [Google Scholar] [CrossRef] [PubMed]
[21] 李嘉励. 多烯磷脂酰胆碱联合异甘草酸镁治疗药物性肝损害疗效观察[J]. 药品评价, 2020, 17(3): 54-55.
[22] 赵艳萍, 杨华, 黄艳辉, 等. 药物性肝损伤针对性治疗的回顾性分析[J]. 中国医院药学杂志, 2019, 39(23): 2424-2427.
[23] 王乐乐, 刘松涛, 唐神结, 等. 抗结核药物性肝损伤的新型生物标志物研究进展[J]. 中华结核和呼吸杂志, 2024, 47(5): 469-474.
[24] Humphries, C. and Dear, J.W. (2023) Novel Biomarkers for Drug-Induced Liver Injury. Clinical Toxicology, 61, 567-572. [Google Scholar] [CrossRef] [PubMed]
[25] Korver, S., Bowen, J., Pearson, K., Gonzalez, R.J., French, N., Park, K., et al. (2021) The Application of Cytokeratin-18 as a Biomarker for Drug-Induced Liver Injury. Archives of Toxicology, 95, 3435-3448. [Google Scholar] [CrossRef] [PubMed]
[26] Danjuma, M.I., Sajid, J., Fatima, H. and Elzouki, A. (2019) Novel Biomarkers for Potential Risk Stratification of Drug Induced Liver Injury (DILI): A Narrative Perspective on Current Trends. Medicine, 98, e18322. [Google Scholar] [CrossRef] [PubMed]
[27] Udomsinprasert, W., Jittikoon, J., Chaikledkaew, U., Saengsiwaritt, W., Chanhom, N., Suvichapanich, S., et al. (2022) Mitochondrial DNA Content as a Diagnostic Marker for Antituberculosis Drug-Induced Liver Injury. International Journal of Infectious Diseases, 122, 1034-1040. [Google Scholar] [CrossRef] [PubMed]